Completed PHASE3 INTERVENTIONAL NCT00086593

Study Of An FDA-approved Drug As Additional Therapy In Patients With Schizophrenia

A Multicenter, Randomized, Double-Blind, Parallel Group Study to Evaluate the Efficacy and Safety of a Flexible Dose of Lamotrigine Compared to Placebo as an Adjunctive Therapy to an Atypical Antipsychotic Agent(s) in Subjects With Schizophrenia

Sponsor: GlaxoSmithKline

Conditions Schizophrenia

Interventions lamotrigine

Updated 7 times since 2017 Last updated: Oct 5, 2016 Started: May 31, 2004 Primary completion: Jul 31, 2005 Completion: Jul 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Schizophrenia, this trial is completed. The trial is conducted by GlaxoSmithKline and has accumulated 7 data snapshots since 2004. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.

Status Flow

Change History

7 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE3
Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

May 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline

Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bedford, United Kingdom , Bellaire, United States , Burlington, Canada , Cambridge, United Kingdom , Coral Springs, United States , Coventry, United Kingdom , Dartmouth, Canada , Edmonton, Canada , Garden Grove, United States , Glasgow, United Kingdom and 27 more locations